Amgen (AMGN) is a publicly traded Healthcare sector company. As of October 20, 2026, AMGN trades at $434.48 with a market cap of $233.82B and a P/E ratio of 24.80. AMGN moved +2.07% today. Year to date, AMGN is +29.70%; over the trailing twelve months it is +42.21%. Its 52-week range spans $261.43 to $447.03. Analyst consensus is buy with an average price target of $403.33. Rallies surfaces AMGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial: Tezspire achieved remission in 69% of patients receiving the 420 mg dose at 24 weeks, versus 3.5% on placebo, in a trial for eosinophilic esophagitis. The companies said remission benefits were maintained through 52 weeks.
| Metric | Value |
|---|---|
| Price | $434.48 |
| Market Cap | $233.82B |
| P/E Ratio | 24.80 |
| EPS | $16.22 |
| Dividend Yield | 2.52% |
| 52-Week High | $447.03 |
| 52-Week Low | $261.43 |
| Volume | 495.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $38.09B |
| Net Income | $8.74B |
| Gross Margin | 69.52% |
27 analysts cover AMGN: 0 strong buy, 9 buy, 16 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $403.33.